AI Science Tracker

Abaucin: a targeted antibiotic against Acinetobacter baumannii

MIT; and McMaster University · 25 May 2023 · medicine

Discovery

Abaucin: a targeted antibiotic against Acinetobacter baumannii

A model trained on about 7,500 compounds screened 6,680 new compounds in under two hours; of 240 tested in the laboratory, nine were antibiotics, including abaucin, which was effective against wound infections in mice. Activity is highly narrow (no effect on the other bacteria tested) and still preclinical.

Technology: Machine learning for compound screening

Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.

Result, AI contribution and limits

Evidence context (descriptions follow the cited sources; test type is a catalog classification):

  • Publication status: Peer-reviewed paper
  • Test type: direct test
  • Tested: About 7,500 molecules were screened in vitro, a neural network predicted new compounds that were tested in the laboratory (about 240 tested, nine antibiotics), and abaucin controlled an A. baumannii infection in a mouse wound model.
  • Still unknown: The abstract states no explicit limitations; the press release says activity is highly narrow (no effect on the other bacteria tested) and the compound remains preclinical.
  • AI role: A neural network trained on screening results predicted structurally new compounds active against A. baumannii.

Evidence sources: https://news.mit.edu/2023/using-ai-scientists-combat-drug-resistant-infections-0525 · https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41589-023-01349-8&resultType=core&format=json

Source checked · editorial details

The source page was checked against this entry. Independent confirmation is not assessed by this label.

Source type: press release. Paper: linked separately.

Review date: 16 Nov 2026. Review scope: Original institutional announcement checked for the specific results, AI contribution and limitations cited in the antibiotic dossier or mathematical follow-up pilot. Full-paper reanalysis, external replication and an exhaustive follow-up search were not performed..

Citations: in the top 1% of works of the same type, year and subfield (OpenAlex work metrics, 420 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.

Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.

Follow-up and relationships
  • same-team extension · 14 Aug 2025: MIT identifies halicin and abaucin as earlier screening results motivating generative design of new NG1/DN1 candidates. The later study does not establish clinical efficacy of these earlier candidates. Source. Recorded 16 Nov 2026.

Follow-up checked 16 Nov 2026 within scope: Bounded check of the original announcements cited by the events recorded here, including explicit links to later program work. This is not an exhaustive literature search or ongoing monitoring commitment..

Directed relationships from this entry; they do not merge catalog counts.

  • 2020-02-halicin · extends: The source explicitly traces this A. baumannii screening study to the earlier halicin program. Distinct candidate and experiment; not independent confirmation of halicin. Source

Open in the full catalog for filters, charts and related discoveries.